NCT07155200View on ClinicalTrials.gov

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

January 31, 2029

Conditions
Small-cell Lung CancerSmall Cell Lung CarcinomaSmall Cell Lung Cancer
Interventions
DRUG

Cirtuvivint

Cirtuvivint will be supplied by Biosplice.

DRUG

Irinotecan

Irinotecan is commercially available.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

Biosplice Therapeutics, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER